although central expert pathology review for quality assurance in cooperative clinical trials involving malignant lymphomas and hodgkin 's disease was put in place by the nci two decades ago , its impact upon patient eligibility for given treatment protocols has never been assessed .
C0024299
malignant lymphomas
C0019829
hodgkin 's disease